Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer.

ABSTRACT: Programmed cell death (PD) protein (ligand [L])-1 inhibitors are established treatments for metastatic non-small cell lung cancer (mNSCLC). In oncology, progression-free survival (PFS) and objective response rate (ORR) are often used as surrogates for overall survival (OS) to inform clinical development; however, there remains uncertainty in the concordance between these endpoints. This study evaluated the impact of a broad set of PD-(L)1 inhibitors on efficacy, explored the relationship between ORR and survival endpoints, and compared PD-1 and PD-L1 treatments for mNSCLC. A dataset of 114 studies was used to conduct a sequential two-stage model-based meta-analysis (MBMA). Firstly, an MBMA with mixed-effects logistic regression was applied to evaluate treatment-specific and clinical covari

SUBMITTER: Franzese RC 

PROVIDER: S-EPMC12917330 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature